Non Regulatory March 31, 2021 Nanoform and Nacuity Pharmaceuticals Sign Technology Proof of Concept (“PoC”) Agreement for Two Ophthalmic Drug Candidates
Non Regulatory March 22, 2021 Nanoform launches next-generation STARMAP® v2.0, the AI-based drug candidate selection tool for CESS®
Non Regulatory February 12, 2021 Invitation to presentation of Nanoform’s year-end report for 2020 on February 26, 2021
Non Regulatory January 11, 2021 Finnish Foundation for Share Promotion and Nasdaq Helsinki has chosen Nanoform as the company of the month (article in Finnish)
Non Regulatory December 23, 2020 Nanoform included in Nasdaq First North 25 index as of Jan 4th, 2021
Non Regulatory December 8, 2020 Notification of major shareholdings according to Nanoform’s Articles of Association
Non Regulatory July 10, 2019 Nanoform appoints Director of Investor Relations following international growth
Non Regulatory May 28, 2019 Nanoform accelerates growth with Director of Project Management appointment
Non Regulatory April 29, 2019 Nanoform strengthens GMP capabilities with Head of Manufacturing appointment
Non Regulatory January 14, 2019 Nanoform set to boost world-class nanonization services with appointment of Chief Technology Officer
Non Regulatory January 7, 2019 Nanoform significantly strengthens commercial organisation with Chief of Business Operations appointment
Non Regulatory December 10, 2018 Nanoform continues rapid expansion with construction of GMP manufacturing plant
Non Regulatory October 29, 2018 Nanoform set to globalize its technology with appointment of a Chief Commercial Officer
Non Regulatory September 19, 2018 Nanoform set to transform drug development through €7 million investment in patented nanoparticle technology
